Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 4/20 | 0.47 |
| ▸ | ELANE | P08246 | 8/20 | 0.45 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | RPA1 | P27694 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | PLAU | P00749 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16532664 | 0.85 | ELANE (0.48) | MAP3K14ELANERPA1F2PLAU | |
| SCHEMBL16516995 | 0.84 | ELANE (0.46) | MAP3K14ELANERPA1F2PLAU | |
| SCHEMBL16516697 | 0.83 | ELANE (0.46) | MAP3K14ELANECNR2CNR1RPA1 | |
| SCHEMBL16517631 | 0.81 | ELANE (0.51) | MAP3K14ELANECNR2CNR1RPA1 | |
| SCHEMBL16517329 | 0.80 | ELANE (0.56) | MAP3K14ELANECNR2CNR1RPA1 | |
| SCHEMBL16532551 | 0.80 | ELANE (0.47) | MAP3K14ELANERPA1F2PLAU | |
| SCHEMBL16517333 | 0.79 | ELANE (0.54) | MAP3K14ELANERPA1F2PLAU | |
| SCHEMBL16517143 | 0.78 | ELANE (0.49) | MAP3K14ELANECNR2CNR1RPA1 | |
| SCHEMBL16517679 | 0.78 | ELANE (0.62) | MAP3K14ELANECNR2CNR1RPA1 | |
| SCHEMBL16516630 | 0.78 | ELANE (0.47) | MAP3K14ELANERPA1F2PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160096850-A9 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096850-A9 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20150065482-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065482-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065482-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | MAP3K14 514/4885ELANE 1188/4885CNR2 836/4885 |
| US-20160096850-A9 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | MAP3K14 514/4885ELANE 1188/4885CNR2 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.